Kornimate/medical-research-clean huggingface dataset:
exploring immunological markers associated with mental fatigue in graves' disease

Conditions: Graves Disease; Graves Ophthalmopathy; Mental Fatigue; Autoimmune Diseases; Thyroid Diseases

Summary: mental fatigue occurs in many diseases and the reasons are mostly unknown. the investigators hypothesize that remaining mental fatigue after restored hyperthyroidism in graves' disease is an autoimmune complication. the aim of this study is to explore immunological markers possibly associated with mental fatigue in graves' disease, which the investigators plan to validate in another study (immunograves wp 2). using a cross-sectional study design, mental fatigue is scored using a questionnaire to find 60 patients with and 60 without mental fatigue 15-60 months after diagnosis of graves disease. the patients and 60 thyroid healthy controls without mental fatigue are assessed for thyroid hormones, quality of life, anxiety and depression, self-evaluated stress, coping strategies, eye symptoms and background variables. scilifelab in stockholm, the national facility for autoimmune profiling, has pre-set large arrays including 42000 human proteins. serum and cerebrospinal fluid will be separately pooled and analysed for a subgroup of patients with or without mental fatigue and for a subgroup of the control group. proteins that preferably bind to antibodies in sera and/or cerebrospinal fluid from graves' patients with mental fatigue in comparison to non-mental fatigue patients, will be screened against the human protein atlas and the allen brain map to identify those proteins that are expressed in the brain. antibodies at higher concentration in the mental fatigue pools compared to the group without mental fatigue will be selected for further analyses on an individual level in the whole cohort together with antibodies targeting g-protein coupled receptors, thyroid autoantibodies, cytokines and biomarkers indicating organic and structural nerve damage.


Eligibility criteria:
inclusion criteria * if patient: graves' disease with positive tsh-receptor antibodies and thyroid hormones above the upper reference limit at diagnosis * diagnosis15 to 60 months ago. if recidive both episodes must have occurred within 15 months to 60 months. * thyroid hormones within normal range without anti thyroid drugs * if control: no thyroid disease * patient and control without mental fatigue: mental fatigue score ≤8 (cut off 10.5) * patient with mental fatigue: mental fatigue score \>13 and debut of symptoms of mental fatigue in parallel with debut of graves' disease, without other obvious cause exclusion criteria * person unable to follow protocol * multiple sclerosis, myalgic encephalomyelitis/chronic fatigue syndrome, any other neurological disease * traumatic brain injury with unconsciousness * other disease strongly associated with fatigue * pregnancy and breast-feeding * on-going or recent systemic treatment with steroids * radioiodine therapy within the last 18 months

Keywords: biomarkers cerebrospinal fluid in graves' disease
a prospective, randomized, clinical study on the effects of cpp-acp-paste, fluoride and a combination on the evolution of white spot lesions in orthodontic patients after debonding.

Conditions: White Spot Lesion; Orthodontic Appliance Complication

Summary: the goal of this randomized clinical trial is to compare the influence of casein phosphopeptide amorphous calcium phosphate (cpp-acp), cpp-acp in combination with fluoride (cpp-acpf), high fluoride concentration, and conventional fluoride toothpaste on the color and size of white spot lesions (wsls) in orthodontic patients following bracket removal.


Eligibility criteria:
inclusion criteria: * patients treated with fixed orthodontic appliances at the ghent university hospital who developed at least three wsls at debonding were included. informed consent had to be obtained from the patient, both verbally and written. exclusion criteria: * patients were excluded from the study if enamel demineralization was already present before orthodontic treatment.

Keywords: orthodontics orthodontic brackets dental caries decalcification caseins fluorides
family-based behavioral treatment for childhood survivors of acute lymphoblastic leukemia

Conditions: Acute Lymphoblastic Leukemia

Summary: a single-arm, non-randomized four-month trial of the adapted family-based behavioral weight loss treatment (fbt) intervention will be conducted to evaluate its acceptability, feasibility, and preliminary indications of efficacy including measures of relative weight change and associated secondary outcomes (e.g., weight related health behaviors, health related quality of life), among 40 childhood acute lymphoblastic leukemia (all) survivors and their families.


Eligibility criteria:
inclusion criteria: * english-speaking caregiver-child dyads * children must be between ages of 5-18 * child must be overweight or obese (defined as a bmi greater than the 85th percentile for their age and sex) * child must have been diagnosed with all * child must have completed their final cancer treatment and currently be in remission * only children and adolescents who have not yet graduated from high school and are living at home with their caregiver at least 50% of the time will be invited to enroll * participating caregivers and children must be able to perform some level of exercise exclusion criteria: * children who are wards of the state * caregivers and/or children who are taking a weight altering medication without being at current dosage for at least six months and weight stable for at least three months * caregivers and/or children who are actively involved in another intensive weight loss program * caregivers and/or children who have undergone weight loss surgery within the last two years and/or who are still losing weight * caregivers and/or children with certain diagnosed psychiatric conditions (e.g., history of/active eating disorder, developmental delays/intellectual disabilities such as down's syndrome and severe presentations of autism spectrum disorder, active suicidal ideation, psychotic symptoms, manic or hypomanic episodes, severe substance use disorder) that would interfere with their ability to participate * caregivers and/or children with certain chronic medical conditions (e.g., type 1 diabetes, muscular dystrophy) for whom participation may be contraindicated

Keywords: overweight/obesity weight management family based behavioral weight loss treatment (fbt)
the natural history study of patients with sanfilippo disease(s) (mps3)

Conditions: Sanfilippo Syndrome; MPS3

Summary: the natural history study of patients with sanfilippo disease(s) (mps3)

this is a natural history study of patients with sanfilippo disease (mps3). patients will be followed over the course of 6 months in which they have blood and urine collected, hearing assessment, complete questionnaires and are evaluated by the principal investigator.

Eligibility criteria:
inclusion criteria: 1. irb - approved informed consent/assent signed by subject and/or parent(s) or legal guardian(s). 2. genetically confirmed diagnosis of mps iii disease genomic dna analysis demonstrating a homozygous or compound heterozygous pathogenic variants in sgsh (type a), naglu (type b), hgsnat (type c), or n- acetylglucosamine-6-sulfatase gns (type d). 3. male or female; five years of age and older 4. negative urine pregnancy test at screening for female subjects with child-bearing potential exclusion criteria: 1. unwilling or unable to follow protocol requirements as per principal investigator 2. any serious or chronic medical illness, including significant cardiac or severe debilitating pulmonary disease as determined by the investigator. 3. any medical condition that, in the opinion of the pi, would place a subject at undue risk 4. inability to cooperate for clinical and safety data collection 5. use of genistein or miglustat within one week of the study 6. evidence of hepatitis b or hepatitis c infection upon serological testing at screening 7. currently participating in another interventional drug trial or has completed an interventional trial less than one month prior to the screening visit
peripheral facial paralysis sequelae in lyme disease among children

Conditions: Lyme Disease

Summary: neuroborreliosis (nb) is the second most frequent manifestation of lyme disease. painful meningoradiculitis is the most common neurologic manifestation in adults while facial nerve palsy (fp) and lymphocytic meningitis is predominant in children. fp is a common reason for pediatric consultation and fp due to lyme borreliosis (lb) represents about 50% of the child's fp in an endemic area. the action to be taken is not formally defined for a child consulting for fp in a lyme disease endemic area. the new recommendations of the high authority of health of june 2018 recommend to carry out a blood serology in first intention, in search of a nb in a child consulting for a peripheral facial paralysis. if this is positive, a lumbar puncture will be performed in search of meningitis. in the case of negative serology, a close clinical surveillance and sometimes serological control is necessary, in order to reassess the diagnosis. in adult recommendations, a lumbar puncture is performed first in any patient consulting for facial paralysis in lb endemic area. the main objective of this study was to describe the clinical and biological characteristics of pediatric nb with fp. others objectives were to describe the diagnostic and therapeutic behavior of a child consulting at university hospital for a facial nerve palsy, to compare the initial gravity of facial nerve palsy, the duration of the paralysis and sequels depending on the diagnosis and treatment initiated.


Eligibility criteria:
inclusion criteria: * children consulting for peripheral facial palsy exclusion criteria: * children consulting for central facial palsy * children with congenital peripheral facial palsy * children with surgery and trauma in the area of the facial nerve, * children with peripheral facial palsy with previous diagnosis * children whose parents refuse the study participation

Keywords: neuroborreliosis facial palsy children
an efficacy trial of low dose all-trans retinoic acid in patients with primary sclerosing cholangitis

Conditions: Cholangitis, Sclerosing

Summary: the purpose of this research study is to determine whether a low dose of atra will improve laboratory tests of liver and bile duct inflammation in patients with psc. the investigators will also look for changes to other blood tests which are related to inflammation, scarring, and the immune system.


Eligibility criteria:
inclusion criteria: * males and females ages 18-80 * diagnosis of large-duct psc based on ercp or mrcp, or liver biopsy findings without alternative explanation for findings, for at least 6 months. * serum alp levels persistently more than 1.5 x upper limit of normal over the past 6 months. * ursodeoxycholic acid therapy must be discontinued for at least 3 months. * at least 2 forms of barrier protection for males and females of child-bearing age. exclusion criteria: * small duct psc, overlap with autoimmune hepatitis, igg4 disease or secondary sclerosing cholangitis. * any malignancy, presently or within the past 5 years, except adequately treated non-melanoma skin cancer, carcinoma in situ of the cervix or in situ prostate cancer. * viral hepatitis including hepatitis a, b, c, d, e. * decompensated cirrhosis, or planned liver transplantation. * recent diagnostic or therapeutic biliary manipulation (endoscopic, radiologic) within the past 3 months. * ascending cholangitis requiring antibiotics within the past 3 months. * uncontrolled ibd, or ibd requiring the use of steroids. * acute or chronic kidney disease with serum creatinine \> 2 mg/dl. * allergy to atra or vitamin a compounds.
attr cardiac amyloidosis in a selected population

Conditions: ATTR Amyloidosis Wild Type; ATTR Gene Mutation; Carpal Tunnel Syndrome; Cardiac Amyloidosis

Summary: patients operated for carpal tunnel syndrome (cts) at ålesund hospital (200 patients) will have a biopsy to diagnose attr amyloidosis. patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis. all patients with positive biopsy will be followed closely for 10 years wit echocardiography an clinically.

biopsy proven attr (v/wt) amyloidosis inpatients operated with cts will undergo standard guidelines recommended examinations as 99mtcdpd spect ct, echocardiography, ecg, holter, genetic testing (v/wt), and lab testing, and cmri as indicated. exclusion of light chain disease will be done. all patients will be followed at least yearly as indicated by guidelines (esc), and patients with development of cardiac amyloidosis will get standard treatment in accordance with guidelines and as approved by the norwegian government. all patients will be followed for 10 years.

Eligibility criteria:
inclusion criteria: * male \> 50 years * female \> 60 years * operated cts at ålesund hospital exclusion criteria: * not consented * do not speak norwegian * secondary cause of cts as traumatic or rheumatic * cannot be followed \> 5 years due to other medical conditions * cardiac disease at time of operation for cts
filling bone erosions: a longitudinal multicentric hr-pqct study of subcutaneous tocilizumab in rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is a chronic inflammatory disease mediated by the production of several cytokines, which leads to the destruction of bone and cartilage tissue in multiple joints and to bone loss. conventional radiographs (cr) are considered as the gold standard for diagnosis and follow up of joint changes in ra. but this method has low sensitivity to detect early erosive changes and is unable to evaluate periarticular bone loss. high resolution peripheral qct (hrpqct) enables the detection of erosions less than 0.5 mm in width or depth at metacarpo-phalangeal (mcp) joints. using 3-d high resolution analysis of cortical bone erosions, this one is also able to evaluate the volumes of erosion and the evolution under treatments il6 (6- interleukin) plays a major role in inflammatory process and bone damages related to ra. tocilizumab (tcz) is a humanized anti-il-6r monoclonal antibody, developed and investigated in several clinical trials in ra. this biotherapy, in association with methotrexate (mtx) or given in monotherapy, is efficient in ra with inadequate response to mtx or anti-tnf b (tumor necrosis factor). tcz reduces dramatically systemic inflammation, structural progression and improves clinical symptoms and quality of life. tocilizumab may help reducing bone erosions, periarticular osteopenia and systemic bone loss.


Eligibility criteria:
inclusion criteria: * active ra, \< 10 years disease duration, diagnosed according to the acr-eular 2010 classification criteria * das 28 superior or equal to 3.2 despite dmard or biological treatment (other than tocilizumab) * superior or equal to one joint erosion at the right or left mcp 2, 3 on x-rays * oral corticosteroid ≤ 10 mg/day prednisone or equivalent stable for at least one month * ra patients eligible to subcutaneous tocilizumab monotherapy exclusion criteria: * treatment with zoledronic acid or denosumab (less than one year) * intra-articular injection of corticosteroids at the mcp in the previous three months * tocilizumab contra-indications in accordance with spc (summary of product characteristics) :hypersensitivity to the active substance or to any of the excipients active, severe infections including active tuberculosis diverticulitis active hepatic disease and hepatic impairment including viral hepatitis elevated alanine aminotransferase or aspartate aminotransferase \>5×uln absolute neutrophil count \< 0.5 × 10 exp 9 /l platelet count \< 50×10 exp 3 /μl, general: * absence of informed consent * prior or planned joint surgery of the hands which might impact the interpretation of imaging assessments.

Keywords: subcutaneous tocilizumab high resolution peripheral qct (hr-pqct) bone erosion bone microarchitecture rheumatoid arthritis
pilot efficacy study of the stendo pulsating suit in patient with leg lymphoedema

Conditions: Primary Lower Limb Lymphedema; Secondary Lower Limb Lymphedema

Summary: this study aims at evaluating the efficacy of the stendo pulsating suit in patients with a leg lymphedema hospitalized for intensive complex decongestive physiotherapy (cdp). this study is a pilot controlled randomized study with two arms.


Eligibility criteria:
inclusion criteria: * patient with a primary or secondary lympedema clinically diagnosed (stemmer sign) of one or two legs. * patient with a lympedema stage ii (persistent) or iii according to the classification of the international society of lymphoedema (isl) * patient aged 18 or more exclusion criteria: * patient with a severe heart, kidney or liver failure, * patient with an advanced obstructive arterial disease * patient with a recent and progressive deep venous thrombosis

Keywords: pulsating suit lymphedema leg volume
virtual technical assistance for child and adult care food program in family child care home

Conditions: Nutrition Poor; Health Behavior

Summary: this study evaluates the effect of a fully virtual nutrition technical assistance training program for family child care home providers on the food they serve young children in their care and the food environment in their home. half the providers will be randomly assigned to the nutrition program and the other half will receive a comparison on environmental health.

early care and education (ece) providers play a vital role in ensuring that young children have access to nutritious foods. over 25% of children in ece (1.2 million children) attend family child care homes (fcch). improvements in the child and adult care food program (cacfp) may introduce new barriers for fcch, which have limited meal preparation capacity. limited research has examined foods served by fcch providers, and no group randomized trials have been conducted using a community-based participatory approach in fcch and including an evaluation of intervention costs. goals: 1. determine the effectiveness of a virtual, rural outreach community-based nutrition technical assistance intervention to enhance meeting cacfp best-practices. methods: conduct a cross-sectional assessment of a random sample of fcch providers' (n=54) menus and meals served. foods will be evaluated against the cacfp requirements and best-practices. trained extension educators will implement both interventions (n=27 intervention, n=27 comparison) focused in rural counties, reaching underserved rural and low-income populations. the intervention is based on theoretical foundations and formative interviews, and will consist of two virtual 60-90-minute one-on-one visits with the fcch and one virtual group class lasting approximately 3 hours.

Eligibility criteria:
inclusion criteria: * family child care home providers who participate in the child and adult care food program in oklahoma. * providers must serve at least 1 2-to-5 year old child and speak english. * providers must plan to continue their business while participating in cacfp for the next 12 months. exclusion criteria: * family child care home providers who care for only infants and toddlers and not speak english. * participant withdraws.

Keywords: early childhood education family childcare home food environment
treatment of malignant strictures in esophagus and gastroesophageal junction with covered or partially covered stent.

Conditions: Esophageal Cancer; Cancer of Gastro Esophageal Junction; Palliative Treatment

Summary: self expandable stent (sems) constitutes the main palliative treatment in advanced esophageal cancer. the palliative effect of sems is immediate when it comes to relief of dysphagia. the duration of this effect is however questionable. the design of sems can be of importance since the device can dislodge and as a consequence of that dysphagia recur. the hypothesis has therefore been formulated that a partially covered sems is associated with less tendency to dislocate as compared to those sems, recently developed, which are covered through their entire length.


Eligibility criteria:
inclusion criteria: * verified squamous cell carcinoma or adenocarcinoma of esophagus or gastro esophageal junction (gej) * age above 18 years. * dysphagia scoring grade two or worse * not amenable for curative treatment * informed consent to participate exclusion criteria: * concomitant cancer disease * inability to comply with study protocol * previous stent treatment * proximal location of the tumour in the esophagus. * need for more than one stent deployment.
regulation of pharyngeal muscle contraction - scor in cardiopulmonary disorders of sleep

Conditions: Lung Diseases; Sleep Apnea Syndromes

Summary: to determine the degree to which neuro-psychological performance and general health status and function may be impaired in subjects with mild and moderate degrees of sleep-related respiratory disturbances (srrd), as compared to subjects with minimal apneic activity. also, to assess the degree to which improvement may occur following specific treatment.

background: the study was a subproject in a specialized center of research in the cardiopulmonary disorders of sleep. frequent sleep-related respiratory disturbances (srrd) have been recognized to occur in as many as 70 percent of elderly and 15 percent of middle-aged subjects. although it is widely agreed that subjects with obvious daytime sleepiness that occurs in association with severe obstructive sleep apnea (respiratory disturbance indices (rdi) \>30) benefit from treatment of their sleep disorders; there is no consensus (and a paucity of data) regarding treatment benefits in subjects with a less profound disorder. rational utilization of health care resources for diagnosis and treatment of sleep apnea requires assessment of whether adverse health effects occur as a consequence of mild or moderate levels of srrd, and whether any such health effects may be reversible with treatment. design narrative: the neuropsychological performance, sleepiness and general functional status were evaluated in 330 subjects, including subjects with little apneic activity (rdi\<5), mild activity (rdi 5-14), and moderate activity (rdi 15-25). of these subjects, 75 percent were selected from a clinic-based sample, and 25 percent were recruited from an ongoing population-based study. 150 subjects with mild and moderate activity were randomized to receive 'conservative' medical therapy (cmt) or cmt plus nasal continuous positive air pressure (cpap) therapy. simple statistics, as well as multivariate techniques, were used to determine the relationship between srrd (and associated hypoxemia, sleep fragmentation, and physiological sleepiness) to: a) intellectual abilities, attention and vigilance, psychomotor performance, learning and memory, and executive functions, and b) to general health status and function. potential benefits of treatment specific for sleep apnea in subjects with mild and moderate srrd were also determined after two months of cpap therapy. the study completion date listed in this record was obtained from the "completed date" entered in the query view report system (qvr).

Eligibility criteria:
no eligibility criteria